3732 results for «2025»
3732 results
International Women's Day 2025: Raising awareness of aortic stenosis in women: - a silent killer
08 Mar 2025
It was a day in October last year when I had a meeting with patients’ group in UK. At the time, I needed to discuss with them why a registry on valvular heart disease and sex disparities is needed. The camaraderie was incredible and the discussion...
Author
Secure your grant for PCR London Valves
Refine your practical skills, improve patient outcomes
Mark your agenda now and prepare to join your peers at the next edition on 10-11 December 2025!
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
21 May 2025 – From EuroPCR 2025
Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.
They review the trial design, patient characteristics, and results, comparing outcomes with...
EuroPCR 2025: RESIL-Card achieves a major milestone - The resilience tool is ready for pilot testing!
20 May 2025
Launched in December 2023 by our community through the ‘We CARE Alliance’ and co-funded by the EU4Health work programme, the mission of the RESIL-Card project is to ensure that essential healthcare services for people with cardiovascular (CV) diseases are maintained during crises. Specifically, the project aims to...
Indirect Industry Supported Grants for #PCRLV
EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
21 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...
Useful links in Interventional Cardiology
12 Oct 2016
We would like to share useful information and links to resources with you on Interventional Cardiology, medical professional societies, specialised websites and scoring tools.
Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies
22 May 2025 – From EuroPCR 2025
Stroke remains one of the most feared complications of TAVI—for both patients and physicians. In this EuroPCR 2025 video interview, Bernard Prendergast and Rajesh Kharbanda examine the role of cerebral protection during TAVI procedures, in light of two randomised trials: PROTECTED TAVR and BHF PROTECT-TAVI. While...
EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years
21 May 2025
Shockwave Medical study confirms benefit of IVL-first strategy in real-world female patients with complex calcified lesions in late-breaking data presentation at EuroPCR 2025
20 May 2025
Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial
03 Sep 2025
Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/whats-new-on-pcronline/2025/esc/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
03 Sep 2025
Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.
Author
TARGET-FIRST: Early aspirin discontinuation after PCI in low-risk acute MI patients
01 Sep 2025
Elad Asher provides his take on the results of TARGET-FIRST presented by Giuseppe Tarantini at the ESC Congress 2025 in Madrid.
Author
DAPT-SHOCK-AMI trial: Cangrelor in cardiogenic shock
03 Sep 2025
Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.
Author
Author
TOP-CABG: the timing of platelet inhibition after coronary artery bypass grafting trial
02 Sep 2025
Jonathan Curio provides his take on TOP-CABG, presented by Xin Yuan at ESC Congress 2025 in Madrid.
Author
